High molecular response rate and overall survival with FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in AML
dc.contributor.author | Othman, J. | |
dc.contributor.author | Potter, N. | |
dc.contributor.author | Mokretar, K. | |
dc.contributor.author | Taussig, D. | |
dc.contributor.author | Khan, A. | |
dc.contributor.author | Krishnamurthy, P. | |
dc.contributor.author | Latif, A. L. | |
dc.contributor.author | Cahalin, P. | |
dc.contributor.author | Aries, J. | |
dc.contributor.author | Amer, M. | |
dc.contributor.author | Belsham, E. | |
dc.contributor.author | Conneally, E. | |
dc.contributor.author | Craddock, C. | |
dc.contributor.author | Culligan, D. | |
dc.contributor.author | Dennis, Michael | |
dc.contributor.author | Duncan, C. | |
dc.contributor.author | Furness, C. | |
dc.contributor.author | Gkreka, P. | |
dc.contributor.author | Hodgson, K. | |
dc.contributor.author | Ingram, W. | |
dc.contributor.author | King, A. | |
dc.contributor.author | Kottaridis, P. | |
dc.contributor.author | McMullin, M. F. | |
dc.contributor.author | Mohite, U. | |
dc.contributor.author | Ngu, L. | |
dc.contributor.author | Patrick, K. | |
dc.contributor.author | Rider, T. | |
dc.contributor.author | Roberts, W. | |
dc.contributor.author | Severinsen, M. T. | |
dc.contributor.author | Storrar, N. | |
dc.contributor.author | Taylor, T. | |
dc.contributor.author | Russell, N. H. | |
dc.contributor.author | Dillon, R. | |
dc.date.accessioned | 2023-03-22T10:52:33Z | |
dc.date.available | 2023-03-22T10:52:33Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, et al. High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML. Blood. 2022 Nov;140:2002-4. PubMed PMID: WOS:000893223202004. | en |
dc.identifier.doi | 10.1182/blood-2022-159503 | en |
dc.identifier.uri | http://hdl.handle.net/10541/626116 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1182/blood-2022-159503 | en |
dc.title | High molecular response rate and overall survival with FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in AML | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Guy's and St Thomas' NHS Foundation Trust, London | en |
dc.identifier.journal | Blood | en |
dc.description.note | en] |